EQS-PVR: Disclosure of Shareholdings
Werte in diesem Artikel
EQS Voting Rights Announcement: BB Biotech AG
Werbung Werbung Disclosure of Shareholdings Notification ID: 77b1d1cb-63b3-4b8f-b0f1-bb767e0006e7
Disclosure notification concerning a single investor PART 1: PERSON SUBJECT TO REPORTING OBLIGATION Last name, first name, place of residence or company name and head office of the beneficial owner (art. 120 para. 1 FMIA) and/ or of the person who has the discretionary power to exercise the voting rights (art. 120 para. 3 FMIA): Werbung Werbung Company: Saba Capital Management, L.P City: New York Country: United States of America (the)
PART 2: IN CASE OF INDIRECT PARTICIPATION Last name, first name, place of residence or company name and head office of the person/s directly involved
PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION Date of the act that creates the obligation to notify: 17.06.2025 Werbung Werbung Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA): X Acquisition Sale Creation of a group Change in group composition Termination of a group Discretionary exercise of voting rights Securities lending and comparable transactions Exercise, non-exercise or expiration of derivative holdings Granting (writing) of derivative holdings Capital increase Capital reduction Ipso jure transfer or transfer due to a decision by a court or public authority Change in the information subject to the obligation to notify Other If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required. Total of voting rights <3% PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA Total of all purchase positions: Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4)
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO: 55,400,000
Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):
The following voting rights were delegated by a third party and can be exercised at one's own discretion.
Voting rights Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled? Yes No
Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings:
2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)
Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):
Total of all sale positions: 55,400,000
Derivative holdings Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:
Total 2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)
23.06.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Internet: | www.bbbiotech.ch |
End of News | EQS News Service |
|
2158408 23.06.2025 CET/CEST
Ausgewählte Hebelprodukte auf BB Biotech
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf BB Biotech
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu BB Biotech AG
Analysen zu BB Biotech AG
Datum | Rating | Analyst | |
---|---|---|---|
21.10.2022 | BB Biotech Add | Baader Bank | |
27.08.2019 | BB BIOTECH neutral | Independent Research GmbH | |
30.04.2015 | BB Biotech accumulate | equinet AG | |
20.04.2015 | BB Biotech buy | Oddo Seydler Bank AG | |
20.04.2015 | BB Biotech Verkaufen | Independent Research GmbH |
Datum | Rating | Analyst | |
---|---|---|---|
21.10.2022 | BB Biotech Add | Baader Bank | |
30.04.2015 | BB Biotech accumulate | equinet AG | |
20.04.2015 | BB Biotech buy | Oddo Seydler Bank AG | |
17.10.2014 | BB Biotech buy | Close Brothers Seydler Research AG | |
21.07.2014 | BB Biotech buy | Close Brothers Seydler Research AG |
Datum | Rating | Analyst | |
---|---|---|---|
27.08.2019 | BB BIOTECH neutral | Independent Research GmbH | |
17.10.2014 | BB Biotech Halten | Independent Research GmbH | |
02.09.2014 | BB Biotech Halten | Independent Research GmbH | |
18.10.2012 | BB Biotech halten | Independent Research GmbH | |
20.07.2012 | BB Biotech halten | Independent Research GmbH |
Datum | Rating | Analyst | |
---|---|---|---|
20.04.2015 | BB Biotech Verkaufen | Independent Research GmbH | |
23.02.2015 | BB Biotech Verkaufen | Independent Research GmbH | |
03.12.2014 | BB Biotech Verkaufen | Independent Research GmbH | |
02.02.2012 | BB Biotech verkaufen | Hamburger Sparkasse AG (Haspa) | |
06.12.2007 | BB BIOTECH ausgestoppt | Der Aktionär |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für BB Biotech AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen